Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enveric Biosciences, Inc.AMRH · Entity 8193 | Director | August 20, 2018 | August 22, 2018 |
| ONE Group Hospitality, Inc.STKS · Entity 7176 | Director | September 30, 2026 | October 02, 2026 |
| STAR EQUITY HOLDINGS, INC.DRAD · Entity 76212 | Director | May 15, 2020 | May 19, 2020 |
| reAlpha Tech Corp.AIRE · Entity 8009 | Director | July 30, 2026 | August 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enveric Biosciences, Inc.
Report date August 20, 2018 · Filed August 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 | Direct | 35,000 |
Reported balance
After 2018-08-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-08-20 · Grant · Acquired 35,000 · Balance 35,000 F1: The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 10,000 |
Reported balance
After 2018-08-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-08-20 · Grant · Acquired 10,000 · Balance 10,000 F2: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3: The Restricted Stock Units vest on the first anniversary of the grant date. |
| Common StockSEC Table I · non-derivative | Direct | 40,990 |
Reported balance
Holding disclosure · report date 2018-08-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 40,990 |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders of the Issuer occurring after August 16, 2018. The options will expire on the fifth anniversary of the vesting date.
F2: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock.
F3: The Restricted Stock Units vest on the first anniversary of the grant date.
ONE Group Hospitality, Inc.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 226,439 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 19,531 · Balance 226,439 |
STAR EQUITY HOLDINGS, INC.
Report date May 15, 2020 · Filed May 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,797 |
Reported balance
After 2020-05-15 transaction · row 1
1 source rowRow 1 · 2020-05-15 · Grant · Acquired 3,797 · Balance 8,797 F1: Award made in accordance with the Digirad Corporation 2018 Incentive Plan (the "Plan") and in lieu of a quarterly cash board retainer fee in the amount of $9,000. The number of shares granted pursuant to the award and the Plan was determined using the closing sales price per share on the grant date (which also equals the price disclosed in this Form 4). |
Filing footnotes · ownership attribution and instrument terms
F1: Award made in accordance with the Digirad Corporation 2018 Incentive Plan (the "Plan") and in lieu of a quarterly cash board retainer fee in the amount of $9,000. The number of shares granted pursuant to the award and the Plan was determined using the closing sales price per share on the grant date (which also equals the price disclosed in this Form 4).
reAlpha Tech Corp.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,644 |
Reported balance
After 2026-07-30 transaction · row 1
1 source rowRow 1 · 2026-07-30 · Grant · Acquired 13,074 · Balance 19,644 F1: Represents shares of common stock issued to the reporting person as quarterly compensation for the quarter ended June 30, 2026, for services as a non-executive director under the issuer's director compensation policy pursuant to its 2022 Equity Incentive Plan, as amended. The number of shares awarded was determined based on the 10-day volume weighted average closing price of the issuer's common stock, as reported on The Nasdaq Stock Market LLC, for the period ending on and including July 30, 2026, which was $1.4341. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued to the reporting person as quarterly compensation for the quarter ended June 30, 2026, for services as a non-executive director under the issuer's director compensation policy pursuant to its 2022 Equity Incentive Plan, as amended. The number of shares awarded was determined based on the 10-day volume weighted average closing price of the issuer's common stock, as reported on The Nasdaq Stock Market LLC, for the period ending on and including July 30, 2026, which was $1.4341.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2018 Filed Jan 3, 2018 21:28 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 8,602 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-18-000043 · form410211002ang_01032018.xml · nonDerivative · entry 1 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 17:14 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | GrantRestricted Stock Unit · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-002088 · form409271ang_08102017.xml · derivative · entry 1 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 8, 2017, subject to the Reporting Person continuing to be a service provider through such date. F2 · derivative.expiration_date: One hundred percent (100%) of the Restricted Stock Units are scheduled to vest on the one (1) year anniversary of August 8, 2017, subject to the Reporting Person continuing to be a service provider through such date. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 18:14 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | Exercise / conversionRestricted Stock Unit · Derivative | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193805-17-001415 · form409271ang_08042017.xml · derivative · entry 2 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date. F1 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: On August 2, 2016 the Reporting Person was granted 12,500 Restricted Stock Units. As to this grant, 100% of the Restricted Stock Units fully vested on August 2, 2017. F3 · derivative.expiration_date: On August 2, 2016 the Reporting Person was granted 12,500 Restricted Stock Units. As to this grant, 100% of the Restricted Stock Units fully vested on August 2, 2017. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 18:14 UTC | STAR EQUITY HOLDINGS, INC. DRAD · Entity 76212 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193805-17-001415 · form409271ang_08042017.xml · nonDerivative · entry 1 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · price: This transaction represents the settlement of Restricted Stock Units in shares of common stock on their scheduled vesting date. Read SEC document |
| May 19, 2017 Filed May 23, 2017 22:16 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 5,941 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001619 · form410211002a_05232017.xml · derivative · entry 2 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,941 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · security: On May 19, 2017, 5,941 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_price: On May 19, 2017, 5,941 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_date: On May 19, 2017, 5,941 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.expiration_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.expiration_date: On May 19, 2017, 5,941 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
| May 19, 2017 Filed May 23, 2017 22:16 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 5,941 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-17-001619 · form410211002a_05232017.xml · nonDerivative · entry 1 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · price: On May 19, 2017, 5,941 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F3 · balance_after: The Form 4 filed for the Reporting Person on May 3, 2017, incorrectly reported the amounts 17,663 and 14,464 in rows 1 and 2 of Column 5 of Table I. The correct numbers should have been 26,803 and 23,604, respectively. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:27 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 9,140 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001278 · form410211a_05032017.xml · derivative · entry 3 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:27 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Tax withholdingCommon Stock | 3,199 | $6.59 | $21,081.41 |
DisclosureSEC source: 0000921895-17-001278 · form410211a_05032017.xml · nonDerivative · entry 2 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,464 F2 · shares: Represents number of shares withheld by the Issuer for the payment of taxes. No shares of Common Stock were sold by the Reporting Person in connection with this transaction. The Reporting Person will retain the net number of shares issued upon the settlement of the RSUs. F3 · price: Closing market price of the Issuer's common stock on the transaction date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:27 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 9,140 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-17-001278 · form410211a_05032017.xml · nonDerivative · entry 1 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. Read SEC document |
| April 11, 2017 Filed Apr 14, 2017 20:25 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantRestricted Stock Unit · Derivative | 8,602 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001058 · form410211002a_04142017.xml · derivative · entry 3 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,602 Underlying: Common Stock · 8,602 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: These Restricted Stock Units are scheduled to vest on January 1, 2018. F3 · derivative.expiration_date: These Restricted Stock Units are scheduled to vest on January 1, 2018. Read SEC document |
| April 11, 2017 Filed Apr 14, 2017 20:25 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantRestricted Stock Unit · Derivative | 9,140 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001058 · form410211002a_04142017.xml · derivative · entry 2 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,140 Underlying: Common Stock · 9,140 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: These Restricted Stock Units are scheduled to vest on May 1, 2017. F2 · derivative.expiration_date: These Restricted Stock Units are scheduled to vest on May 1, 2017. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 21:31 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 17,663 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-000108 · form410211002a_01262017.xml · derivative · entry 2 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,663 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · security: On January 24, 2017, 17,663 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_price: On January 24, 2017, 17,663 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_date: On January 24, 2017, 17,663 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.expiration_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.expiration_date: On January 24, 2017, 17,663 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 21:31 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 17,663 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-17-000108 · form410211002a_01262017.xml · nonDerivative · entry 1 Angelis Dimitrios · CIK 0001595628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · price: On January 24, 2017, 17,663 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.